Inovio Pharmaceuticals, Inc.INONASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank72
5Y CAGR-1.8%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-1.8%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.60% |
| Q3 2025 | 8.12% |
| Q2 2025 | 7.85% |
| Q1 2025 | -22.98% |
| Q4 2024 | 25.52% |
| Q3 2024 | 17.62% |
| Q2 2024 | -5.44% |
| Q1 2024 | -14.93% |
| Q4 2023 | 22.95% |
| Q3 2023 | 4.02% |
| Q2 2023 | 15.72% |
| Q1 2023 | 21.44% |
| Q4 2022 | -56.46% |
| Q3 2022 | 65.66% |
| Q2 2022 | -45.17% |
| Q1 2022 | 32.01% |
| Q4 2021 | -75.98% |
| Q3 2021 | 27.94% |
| Q2 2021 | -58.32% |
| Q1 2021 | -79.13% |
| Q4 2020 | 19.24% |
| Q3 2020 | -9.49% |
| Q2 2020 | -31.50% |
| Q1 2020 | 17.06% |
| Q4 2019 | -27.01% |
| Q3 2019 | 15.07% |
| Q2 2019 | 1.17% |
| Q1 2019 | 3.27% |
| Q4 2018 | -10.72% |
| Q3 2018 | -412.05% |
| Q2 2018 | 84.11% |
| Q1 2018 | -43.07% |
| Q4 2017 | 21.58% |
| Q3 2017 | -202.89% |
| Q2 2017 | 56.07% |
| Q1 2017 | 1.92% |
| Q4 2016 | -10.73% |
| Q3 2016 | -10.80% |
| Q2 2016 | -17.97% |
| Q1 2016 | -6.36% |